| Literature DB >> 27274733 |
Abstract
Stem cell-derived neurons from various source materials present unique model systems to examine the fundamental properties of central nervous system (CNS) development as well as the molecular underpinnings of disease phenotypes. In order to more accurately assess potential therapies for neurological disorders, multiple strategies have been employed in recent years to produce neuronal populations that accurately represent in vivo regional and transmitter phenotypes. These include new technologies such as direct conversion of somatic cell types into neurons and glia which may accelerate maturation and retain genetic hallmarks of aging. In addition, novel forms of genetic manipulations have brought human stem cells nearly on par with those of rodent with respect to gene targeting. For neurons of the CNS, the ultimate phenotypic characterization lies with their ability to recapitulate functional properties such as passive and active membrane characteristics, synaptic activity, and plasticity. These features critically depend on the coordinated expression and localization of hundreds of ion channels and receptors, as well as scaffolding and signaling molecules. In this review I will highlight the current state of knowledge regarding functional properties of human stem cell-derived neurons, with a primary focus on pluripotent stem cells. While significant advances have been made, critical hurdles must be overcome in order for this technology to support progression toward clinical applications.Entities:
Year: 2016 PMID: 27274733 PMCID: PMC4870377 DOI: 10.1155/2016/4190438
Source DB: PubMed Journal: Stem Cells Int Impact factor: 5.443
Dysfunction and treatment of diseased human stem cell-derived neurons.
| Disease | Cell type(s) | Observed phenotypes | Refs | Treatment |
|---|---|---|---|---|
| Amyotrophic lateral sclerosis (ALS) | iPSC-derived motor neurons | Motor neurons derived from ALS iPSCs displayed hyperexcitability | [ | Kv7 channel-activator retigabine reversed MN hyperexcitability |
|
| ||||
| Bipolar disorder | Forebrain hPSNs | Increased AP frequency and amplitude in lithium-responsive and -nonresponsive hPSNs selectively responded to treatments (column 5) | [ | Li2+ reduced hyperexcitability in hPSNs from Li2+-responsive patients |
|
| ||||
| Down syndrome | Forebrain hPSNs | Decreased frequency (not amplitude) of spontaneous excitatory and inhibitory synaptic events | [ | None reported |
|
| ||||
| Dravet syndrome | Forebrain hPSNs | (i) Spike generation impaired in GABAergic neurons | [ | Phenytoin reduced hyperexcitability |
| (ii) Increased sodium currents | [ | |||
| (iii) Hyperexcitability/spontaneous bursting resembling epileptiform activity | [ | |||
|
| ||||
| Huntington's disease | Forebrain and striatal hPSNs | CAG repeat length-dependent reductions in spiking associated with increased cell death | [ | None reported |
|
| ||||
| Phelan-McDermid syndrome (22q13 deletion) | Forebrain hPSNs | Selective reduction in amplitude and frequency of spontaneous excitatory postsynaptic currents (excitation-inhibition ratio altered) | [ | Genetic expression of Shank3 or IGF1 treatment restored EPSCs |
|
| ||||
| Psychiatric disease | Forebrain hPSNs and iNs | Impaired neurotransmitter release; reduced sEPSC frequency upregulation of presynaptic CASK protein | [ | None reported |
|
| ||||
| Rett syndrome | Glutamatergic hPSNs | Decreased activity-dependent calcium oscillations | [ | None reported |
|
| ||||
| Spinal muscular atrophy (SMA) | iPSC-derived motor neurons | Hyperexcitability and impaired neurotransmission | [ | Genetic correction reversed phenotypes |
|
| ||||
| Timothy syndrome | Forebrain hPSNs | Increased action potential width | [ | None reported |
|
| ||||
| Williams-Beuren syndrome | Forebrain hPSNs | Reduced AP amplitude and prolonged decay; no effect on other passive/active conductance nor mEPSCs | [ | None reported |
| Cell type | hESCs (primed) | iPSCs (primed) | iNs |
|---|---|---|---|
| Efficiency | >90% | Variable (up to 90%) | Low (2–11%) |
|
| |||
| Time to functional maturity | 5 weeks + | 5 weeks + | 2 weeks + |
|
| |||
| Epigenome status | Embryonic (open) | Some adult modifications retained | Adult modifications maintained |
|
| |||
| Cell types produced | Neurons (many subtypes), astrocytes, oligodendrocytes | Neurons (many subtypes), astrocytes, oligodendrocytes | Primarily glutamatergic neurons |
|
| |||
| Purity of phenotypes | Heterogeneous (<80% pure) | Heterogeneous (<80% pure) | Relatively pure (>80%) |
|
| |||
| Effect of astrocytes | Accelerates maturation | Accelerates maturation | Required for functional maturation |
|
| |||
| Genetic intervention | N/A | Required | Required |
|
| |||
| Developmental studies | Appropriate | Appropriate | Less appropriate |
|
| |||
| Culture duration | Months | Months | Weeks |